Want to see RLMD full AI Analyst Report?
RLMD Stock Chart & Stats
$7.48
-$0.01(-3.06%)
At close: 4:00 PM EST
$7.48
-$0.01(-3.06%)
Day’s Range― - ―
52-Week Range$0.55 - $8.00
Previous CloseN/A
Volume447.03K
Average Volume (3M)2.23M
Market Cap
$549.62M
Enterprise Value$368.75
Total Cash (Recent Filing)$233.96M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.69
Next Earnings
Aug 06, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.11
Shares Outstanding104,890,220
10 Day Avg. Volume1,717,556
30 Day Avg. Volume2,229,225
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.20
Price to Sales (P/S)0.00
P/FCF Ratio-4.16
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$14.33Price Target Upside91.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.8
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy & SafetyThe Phase 2 dataset shows exceptionally high and durable complete response rates with no severe treatment-related adverse events. This durable clinical profile, if reproduced in Phase 3, strengthens the drug’s regulatory and commercial case, supports physician adoption in-office, and reduces downstream safety-related commercialization risk.
Regulatory Pathway ClarityClear FDA alignment and a defined two-pathway registrational plan materially reduce regulatory ambiguity. A well-defined IND and mid-2026 start schedule provide predictable development milestones, allow targeted trial design, and improve the company’s ability to plan resources and partnerships for pivotal-readout milestones.
Strengthened Balance SheetA substantial financing boosted cash to $234M with stated runway into 2029, which materially de-risks near- and mid-term execution for planned Phase 3 programs. This funding reduces immediate dilution pressure, enables enrollment and manufacturing planning, and supports selective pipeline work without urgent fundraising.
Bears Say
Pre‑revenue Cash BurnRelmada remains a pre-revenue biotech with operating and free cash flow persistently negative. Even with current runway, recurring cash burn means ongoing funding risk beyond stated horizons, constrains long-term financial flexibility, and creates pressure for future capital raises that can dilute shareholders.
Rising G&A And LossesAn ~81% jump in G&A driven by compensation and a larger absolute net loss indicate higher fixed overhead as the company scales. Sustained elevated SG&A reduces available funds for R&D and trials, widens required future funding, and can pressure margins and execution efficiency if not managed.
Equity Dilution RiskThe authorized share increase structurally enables additional equity issuance for financing, acquisitions, or compensation. Given the pre-revenue profile and historical reliance on external funding, this raises the probability of future dilution, which can meaningfully affect long-term shareholder returns even if needed to fund development.
Relmada Therapeutics News
RLMD FAQ
What was Relmada Therapeutics Inc’s price range in the past 12 months?
Relmada Therapeutics Inc lowest stock price was $0.55 and its highest was $8.00 in the past 12 months.
What is Relmada Therapeutics Inc’s market cap?
Relmada Therapeutics Inc’s market cap is $549.62M.
When is Relmada Therapeutics Inc’s upcoming earnings report date?
Relmada Therapeutics Inc’s upcoming earnings report date is Aug 06, 2026 which is in 16 days.
How were Relmada Therapeutics Inc’s earnings last quarter?
Relmada Therapeutics Inc released its earnings results on May 12, 2026. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of -$0.2 by -$0.02.
Is Relmada Therapeutics Inc overvalued?
According to Wall Street analysts Relmada Therapeutics Inc’s price is currently Undervalued.
Does Relmada Therapeutics Inc pay dividends?
Relmada Therapeutics Inc does not currently pay dividends.
What is Relmada Therapeutics Inc’s EPS estimate?
Relmada Therapeutics Inc’s EPS estimate is -0.2.
How many shares outstanding does Relmada Therapeutics Inc have?
Relmada Therapeutics Inc has 104,890,220 shares outstanding.
What happened to Relmada Therapeutics Inc’s price movement after its last earnings report?
Relmada Therapeutics Inc reported an EPS of -$0.22 in its last earnings report, missing expectations of -$0.2. Following the earnings report the stock price went up 0.537%.
Which hedge fund is a major shareholder of Relmada Therapeutics Inc?
Currently, no hedge funds are holding shares in RLMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Relmada Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.33 (91.62% Upside)
$14.33 (91.62% Upside)
Blogger Sentiment
Bullish
RLMD Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 3.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
780.67%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
750.32%
Trailing 12-Months
Company Description
Relmada Therapeutics Inc
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
RLMD Stock 12 Month Forecast
Average Price Target
$14.33
▲(91.62% Upside)
Technical Analysis
Ownership Overview
2.87% Insiders
3.74% Mutual Funds
47.67% Other Institutional Investors
34.54% Public Companies and
Individual Investors